HK1107699A1 - Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound - Google Patents

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound

Info

Publication number
HK1107699A1
HK1107699A1 HK07113471.4A HK07113471A HK1107699A1 HK 1107699 A1 HK1107699 A1 HK 1107699A1 HK 07113471 A HK07113471 A HK 07113471A HK 1107699 A1 HK1107699 A1 HK 1107699A1
Authority
HK
Hong Kong
Prior art keywords
analogous compound
ritonavir
ritonavir analogous
preparation
pharmaceutical composition
Prior art date
Application number
HK07113471.4A
Other languages
English (en)
Inventor
Maria Alice Bockelmann
Simone Soares Rosatto
Claudio Roberto Fuzeto
Thiago Boscaro Vernucci
Daniela Cecilia Barel
Moraes Godinho De Oliveira Kesley
Puggina De Freitas M D Matheus
Original Assignee
Cristalia Prod Quimicos Farm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm filed Critical Cristalia Prod Quimicos Farm
Publication of HK1107699A1 publication Critical patent/HK1107699A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07113471.4A 2004-05-13 2007-12-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound HK1107699A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0401742A BRPI0401742B8 (pt) 2004-05-13 2004-05-13 composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
PCT/BR2005/000077 WO2005111006A1 (en) 2004-05-13 2005-05-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.

Publications (1)

Publication Number Publication Date
HK1107699A1 true HK1107699A1 (en) 2008-04-11

Family

ID=36072150

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07113471.4A HK1107699A1 (en) 2004-05-13 2007-12-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound

Country Status (10)

Country Link
US (1) US7763733B2 (es)
EP (1) EP1751125B1 (es)
JP (1) JP4993747B2 (es)
CN (1) CN100584833C (es)
AT (1) ATE480526T1 (es)
BR (1) BRPI0401742B8 (es)
DE (1) DE602005023437D1 (es)
HK (1) HK1107699A1 (es)
MX (1) MXPA06013188A (es)
WO (1) WO2005111006A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140004808A (ko) 2006-07-07 2014-01-13 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
EP2081917A2 (en) * 2006-08-31 2009-07-29 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
DK2487166T3 (en) 2007-02-23 2017-02-20 Gilead Sciences Inc Modulators of the pharmacokinetic properties of therapeutics
CA2692331A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN102786494B (zh) * 2012-07-26 2016-01-06 合肥华方医药科技有限公司 利托那韦异构体杂质的合成研究及控制方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir

Also Published As

Publication number Publication date
EP1751125A1 (en) 2007-02-14
BRPI0401742A (pt) 2006-01-10
WO2005111006A1 (en) 2005-11-24
JP4993747B2 (ja) 2012-08-08
MXPA06013188A (es) 2007-02-14
ATE480526T1 (de) 2010-09-15
BRPI0401742B8 (pt) 2021-05-25
EP1751125B1 (en) 2010-09-08
DE602005023437D1 (de) 2010-10-21
CN100584833C (zh) 2010-01-27
BRPI0401742B1 (pt) 2019-04-16
US7763733B2 (en) 2010-07-27
US20070244168A1 (en) 2007-10-18
CN1980907A (zh) 2007-06-13
JP2007537166A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
UA96449C2 (en) Stable laquinimod preparations
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2009055006A8 (en) Deuterated darunavir
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
TW200806300A (en) New therapeutic combinations for the treatment of depression
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
TW200626158A (en) Naphthaline derivatives
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
HK1107699A1 (en) Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
WO2006113718A3 (en) Compositions for the treatment of neoplasms
MX2007008585A (es) Compuestos peptidicos.
WO2005056577A3 (en) Peptide inhibitors of hiv

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160511